Preparation and evaluation of fexofenadine microemulsions for intranasal delivery

International Journal of Pharmaceutics

Volumn 395, Issue 1-2, 2010, Pages 309-316

  Piao, Hong Mei ^a   Balakrishnan, Prabagar ^a   Cho, Hyun Jong ^a   Kim, Hyunjun ^b   Kim, You Sun ^b   Chung, Suk Jae ^a   Shim, Chang Koo ^a   Kim, Dae Duk ^a  

^a Seoul National University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Allergic rhinitis; Fexofenadine; Intranasal delivery; Microemulsion

Indexed keywords

FEXOFENADINE; LABRASOL; LAUROGLYCOL 90; MACROGOL 400; PLUROL OLEIQUE CC 497; POLYGLYCERYL OLEATE; PROPYLENE GLYCOL MONOLAURATE; SURFACTANT; UNCLASSIFIED DRUG; EMULSION; GLYCOL; HISTAMINE H1 RECEPTOR ANTAGONIST; MACROGOL DERIVATIVE; OIL; ORGANIC COMPOUND; TERFENADINE;

ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG SOLUBILITY; HISTOPATHOLOGY; MALE; MICROEMULSION; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCOSITY; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG FORMULATION; EMULSION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; EMULSIONS; GLYCOLS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; INJECTIONS, INTRAVENOUS; MALE; NASAL MUCOSA; OILS; ORGANIC CHEMICALS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL; TERFENADINE; VISCOSITY;

EID: 77954310517     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.05.041     Document Type: Article

References (40)

1. Aurora J. Development of nasal delivery system: a review. Drug Deliv. Technol. 2002, 2:70-73.
2. Balakrishnan P., Lee B.J., Oh D.H., Kim J.O., Lee Y.I., Kim D.D., Jee J.P., Lee Y.B., Woo J.S., Yong C.S., Choi H.G. Enhanced oral bioavailability of coenzyme Q10 by self-emulsifying drug delivery systems. Int. J. Pharm. 2009, 374:66-72.
3. Balakrishnan P., Lee B.J., Oh D.H., Kim J.O., Hong M.J., Jee J.P., Kim J.A., Yoo B.K., Woo J.S., Yong C.S., Choi H.G. Enhanced oral bioavailability of dexibuprofen by a novel solid SEDDS formulation. Eur. J. Pharm. Biopharm. 2009, 72:539-545.
4. Baroody F.M. Allergic rhinitis: broader disease effects and implications for management. Otolaryngol. Head Neck Surg. 2003, 128:616-631.
5. Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R. D. 2007, 8:301-314.
6. Chidambaram N., Burgess D.J. A novel in vitro release method for submicron sized dispersed systems. AAPS Pharm. Sci. 1998, 1:E11.
7. Costantino H.R., Illum L., Brandt G., Johnson P.H., Quay S.C. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm. 2007, 337:1-24.
8. Cornaire G., Woodley J., Hermann P., Cloarec A., Arellano C., Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 2004, 278:119-131.
9. Constantinides P.P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 1995, 12:1561-1572.
10. Daley-Yates P.T., Price A.C., Sisson J.R., Pereira A., Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br. J. Clin. Pharmacol. 2001, 51:400-409.
11. Djekic L., Primorac M. The influence of cosurfactants and oils on the formation of pharmaceutical microemulsions based on PEG-8 caprylic/capric glycerides. Int. J. Pharm. 2008, 352:231-239.
12. Drescher S., Schaeffeler E., Hitzl M., Hofmann U., Schwab M., Brinkmann U., Eichelbaum M., Fromm M.F. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 2002, 53:526-534.
13. Elshafeey A.H., Bendas E.R., Mohamed O.H. Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. AAPS Pharm. Sci. Technol. 2009, 10:2.
14. Ferri J.K., Stebe K.J. Which surfactants reduce surface tension faster? A scaling argument for diffusion-controlled adsorption. Adv. Colloid Interface Sci. 2000, 85:61-97.
15. Furubayashi T., Inoue D., Kamaguchi A., Higashi Y., Sakane T. Influence of formulation viscosity on drug absorption following nasal application in rats. Drug Metab. Pharmacokinet. 2007, 22:206-211.
16. Ghosh P.K., Majithiya R.J., Umrethia M.L., Murthy R.S. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS Pharm. Sci. Technol. 2006, 7:E77.
17. Hernández-Escobar S.A., Avila-Casado M.C., Soto-Abraham V., López Escudero O.L., Soto M.E., Vega-Bravo M.L., Fortoul van der Goes T., Reyes-Maldonado E. Cytological damage of nasal epithelium associated with decreased glutathione peroxidase in residents from a heavily polluted city. Int. Arch. Occup. Environ. Health 2009, 82:603-612.
18. Huh Y., Cho H.J., Yoon I.S., Choi M.K., Kim J.S., Oh E., Chung S.J., Shim C.K., Kim D.D. Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride. Eur. J. Pharm. Sci. 2010, 40:9-15.
19. Illum, L., Watts, P.J., Cheng, Y.-H., 2001. Novel formulations of fexofenadine. United States West Pharmaceutical Services Drug Delivery & Clinical Research Centre, Ltd. 20010051613. Available from: http://www.freepatentsonline.com/y2001/0051613.html.
20. Jadhav K.R., Shaikh I.M., Ambade K.W., Kadam V.J. Applications of microemulsion based drug delivery system. Curr. Drug Deliv. 2006, 3:267-273.
21. John H.K. Allergic rhinitis: current pharmacotherapy. Otolaryngol Clin. North Am. 2008, 41:347-358.
22. Kandimalla K.K., Donovan M.D. Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Pharm. Res. 2005, 22:1121-1128.
23. Koga K., Kusawake Y., Ito Y., Sugioka N., Shibata N., Takada K. Enhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur. J. Pharm. Biopharm. 2006, 64:82-91.
24. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50:47-60.
25. Li L., Nandi I., Kim K.H. Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. Int. J. Pharm. 2002, 237:77-85.
26. Lin H., Gebhardt M., Bian S., Kwon K.A., Shim C.-K., Chung S.-J., Kim D.-D. Enhancing effect of surfactants on fexofenadine-HCl transport across the human nasal epithelial cell monolayer. Int. J. Pharm. 2007, 330:23-31.
27. Lin Y., Shen Q., Katsumi H., Okada N., Fujita T., Jiang X., Yamamoto A. Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats. Biol. Pharm. Bull. 2007, 30:1301-1307.
28. Mainardes R.M., Urban M.C., Cinto P.O., Chaud M.V., Evangelista R.C., Gremião M.P. Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery. Curr. Drug Deliv. 2006, 3:275-285.
29. Olsén L., Ingvast-Larsson C., Larsson P., Broström H., Bondesson U., Sundqvist M., Tjälve H. Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. J. Vet. Pharmacol. Ther. 2006, 29:129-135.
30. Pilpot E.E. Safety of second generation antihistamines. Allergy Asthma Proc. 2000, 2:15-20.
31. Pontiroli A.E., Calderara A., Perfetti M.G., Bareggi S.R. Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients. Eur. J. Clin. Pharmacol. 1993, 45:555-558.
32. Rhee Y.S., Choi J.G., Park E.S., Chi S.C. Transdermal delivery of ketoprofen using microemulsions. Int. J. Pharm. 2001, 228:161-170.
33. Shimizu M., Uno T., Sugawara K., Tateishi T. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br. J. Clin. Pharmacol. 2006, 61:538-544.
34. Straszek S.P., Pedersen O.F. Nasal cavity dimensions in guinea pig and rat measured by acoustic rhinometry and fluid-displacement method. J. Appl. Physiol. 2004, 96:2109-2114.
35. Strelevitz T.J., Foti R.S., Fisher M.B. In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J. Pharm. Sci. 2006, 95:1334-1341.
36. Tomoyuki F., Daisuke I., Akiko K., Yutaka H., Toshiyasu S. Influence of formulation viscosity on drug absorption following nasal application in rats. Drug Metab. Pharmacokinet. 2007, 22:206-211.
37. Ugwoke M.I., Agu R.U., Verbeke N., Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 2005, 57:1640-1665.
38. Wioland M.A., Fleury-Feith J., Corlieu P., Commo F., Monceaux G., Lacau-St-Guily J., Bernaudin J.F. CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. J. Histochem. Cytochem. 2000, 48:1215-1222.
39. Yin Y.M., Cui F.D., Mu C.F., Choi M.K., Kim J.S., Chung S.J., Shim C.K., Kim D.D. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J. Control. Release 2009, 140:86-94.
40. Zhang Q., Jiang X., Jiang W., Lu W., Su L., Shi Z. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int. J. Pharm. 2004, 275:85-96.